Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...

AstraZeneca PLC AZN shares inched down 0.40% to £119.68 Tuesday, on what proved to be an all-around great trading session for ...

The AstraZeneca PLC ADR AZN inched 0.98% higher to $79.04 Monday, on what proved to be an all-around mixed trading session ...

AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...

Imfinzi is a human monoclonal antibody that targets the PD-L1 protein, whereas Imjudo focuses on the CTLA-4 protein.

If the trial design doesn't cause regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated ...

AstraZeneca's Dato-DXd faces challenges in overall survival data but holds potential for approval with promising PFS benefits ...

A healthy 27-year-old died from a reaction to the AstraZeneca vaccine after NHS mistakes meant he wrongly got the jab, a report has found.

AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.

As if a limited initial FDA approval was not bad enough, AstraZeneca’s Truqap has recorded a pivotal trial flop that could ...

AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has failed to improve overall survival (OS) in ...